Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

126.45 +0.60 (+0.48%)
Official Closing Price Updated: 7:00 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,786,756
Open 126.53
Bid (Size) 125.50 (1)
Ask (Size) 127.00 (1)
Prev. Close 125.85
Today's Range 124.91 - 126.60
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Merck & Co Unusual Options Activity
Via Benzinga

Performance

YTD
+11.67%
+11.67%
1 Month
-3.23%
-3.23%
3 Month
-0.09%
-0.09%
6 Month
+7.73%
+7.73%
1 Year
+15.00%
+15.00%

More News

Read More
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
Via InvestorPlace
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Via Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
Via InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
Via InvestorPlace
What's Going On With Merck Stock On Friday?
Via Benzinga
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc
Via Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
From Merck & Co., Inc.
Via Business Wire
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
This Recent FDA Approval Is Bad News for Pfizer
Via The Motley Fool
Exposures Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Via Benzinga
Exposures Product Safety
These Are The Best Dow Jones Stocks Of 2024 Thus Far
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
From Daiichi Sankyo
Via Business Wire
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Via Benzinga
7 Dividend Stocks to Buy Now for Enhanced Returns
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.